Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 6/20 | 0.47 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154644 | 0.86 | THRB (0.53) | THRBMAPK1LMNAIDO1SCN9A | |
| SCHEMBL1153375 | 0.86 | THRB (0.53) | THRBMAPK1LMNAIDO1SCN9A | |
| SCHEMBL1154291 | 0.86 | THRB (0.53) | THRBMAPK1LMNAIDO1SCN9A | |
| SCHEMBL1154417 | 0.85 | THRB (0.51) | THRBMAPK1LMNAIDO1SCN9A | |
| SCHEMBL1154322 | 0.83 | KMT2A (0.49) | THRBMAPK1LMNAIDO1SCN9A | |
| SCHEMBL1153779 | 0.81 | LMNA (0.61) | LMNAMAPTNPSR1LIPERAB9A | |
| SCHEMBL971589 | 0.80 | MAPT (0.63) | THRBLMNAIDO1MAPTNPSR1 | |
| SCHEMBL1154439 | 0.80 | KMT2A (0.51) | THRBMAPK1LMNAIDO1SCN9A | |
| SCHEMBL8020738 | 0.78 | THRB (0.57) | THRBMAPK1LMNASCN9AMAPT | |
| SCHEMBL1153793 | 0.78 | TSHR (0.50) | THRBMAPK1LMNAIDO1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | BASF SE (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2252606-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101079-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009101078-A1 | PYRIMIDYLMETHYL SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039693-A1 | Pyrimidylmethyl Sulfonamide Compounds | TPMT, NQO2, TST | THRB 3469/4885MAPK1 1784/4885LMNA 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.